| Autor: |
Schmidt, Sarah, Mengistu, Meron, Daffis, Stephane, Ahmadi-Erber, Sarah, Deutschmann, Daniela, Grigoriev, Tetiana, Chu, Ruth, Leung, Cleo, Tomkinson, Adrian, Uddin, Mohammad Nizam, Moshkani, Safiehkhatoon, Robek, Michael D, Perry, Jason, Lauterbach, Henning, Orlinger, Klaus, Fletcher, Simon P, Balsitis, Scott |
| Předmět: |
|
| Zdroj: |
Journal of Infectious Diseases; 4/15/2024, Vol. 229 Issue 4, p1077-1087, 11p |
| Abstrakt: |
Hepatitis B Virus (HBV) is a major driver of infectious disease mortality. Curative therapies are needed and ideally should induce CD8 T cell-mediated clearance of infected hepatocytes plus anti-hepatitis B surface antigen (HBsAg) antibodies (anti-HBs) to neutralize residual virus. We developed a novel therapeutic vaccine using non-replicating arenavirus vectors. Antigens were screened for genotype conservation and magnitude and genotype reactivity of T cell response, then cloned into Pichinde virus (PICV) vectors (recombinant PICV, GS-2829) and lymphocytic choriomeningitis virus (LCMV) vectors (replication-incompetent, GS-6779). Alternating immunizations with GS-2829 and GS-6779 induced high-magnitude HBV T cell responses, and high anti-HBs titers. Dose schedule optimization in macaques achieved strong polyfunctional CD8 T cell responses against core, HBsAg, and polymerase and high titer anti-HBs. In AAV-HBV mice, GS-2829 and GS-6779 were efficacious in animals with low pre-treatment serum HBsAg. Based on these results, GS-2829 and GS-6779 could become a central component of cure regimens. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
